Bruges, Belgium

Lieven Elvire Colette Baert

This inventor holds 17 USPTO granted patents and 14 published patent applications, plus 10 CIPO patents and 12 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Janssen Sciences Ireland Unlimited Company, Janssen Pharmaceutica Nv, Janssen R&d Ireland. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lieven Elvire Colette Baert. Retrieved from https://idiyas.com/inventor/lieven-elvire-colette-baert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 76.5

 

 

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 40(Granted Patents)


Location History:

  • Brugge, BE (2002 - 2014)
  • Bruges, BE (2003 - 2022)

Company Filing History:


Years Active: 2002-2024

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
HIV Treatment
Degradable Implants
Antifungal Compositions
Pharmacokinetics
Polyinosinic-Polycytidylic Acid
Sustained Release
Crystalline Form
Powders for Reconstitution
Spray Dried Formulations
Co-Crystal
Bioavailability
Solid Mixtures
17 patents (USPTO):Explore Patents

Title: Lieven Elvire Colette Baert: A Prolific Innovator in Pharmaceutical Technologies

Introduction:

Lieven Elvire Colette Baert, an esteemed inventor based in Bruges, Belgium, has made significant contributions to the field of pharmaceutical technologies. With 16 patents to his name, Baert's innovative work focuses on the development of degradable, sustainable drug delivery systems. This article explores Baert's latest patents, career highlights, notable collaborations, and summarizes his impressive contributions to the healthcare industry.

Latest Patents:

Among Baert's notable patents is the "Degradable Removable Implant for the Sustained Release of an Active Compound." This patent showcases Baert's expertise in creating pharmaceutical implants that release drugs over an extended period. The implant consists of a tube made of a degradable polymer, containing micro-particles that contain one or more active agents. By controlling the size of the micro-particles, Baert ensures that the majority remain within the tube, dispensing the active agent gradually.

Another pioneering invention by Baert is "Aqueous Suspensions of TMC278," which focuses on pharmaceutical compositions for intramuscular or subcutaneous injections. These compositions utilize micro- or nanoparticles, suspended in a pharmaceutically acceptable carrier. Baert's innovation specifically addresses the treatment and prevention of HIV infection, showcasing his commitment to finding solutions for critical health issues.

Career Highlights:

Throughout his career, Baert has held positions at renowned pharmaceutical companies, including Janssen Sciences and Janssen Pharmaceutica. These organizations have provided Baert with a platform to translate his innovative ideas into practical solutions. Baert's impactful contributions and dedication to advancing pharmaceutical technologies have earned him recognition within the industry.

Collaborations:

Baert has worked closely with esteemed colleagues, including Geert Verreck and Guenter Kraus. Collaborations enable inventors to leverage their collective expertise, resulting in breakthrough innovations. Baert's collaborations signify his commitment to knowledge sharing and his ability to drive meaningful progress by working alongside other industry experts.

Conclusion:

Lieven Elvire Colette Baert's inventive spirit and remarkable contributions to pharmaceutical technologies have cemented his position as a prominent figure in the field. With expertise in developing degradable drug delivery systems and focusing on critical healthcare challenges like HIV, Baert has demonstrated an unwavering commitment to bettering the lives of patients. As he continues to innovate and collaborate with industry leaders, the impact of his work within the healthcare sector is likely to grow, inspiring future generations of inventors to push the boundaries of pharmaceutical technologies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…